Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol 2016 Mar;172(5):685-98
Date
01/23/2016Pubmed ID
26791002DOI
10.1111/bjh.13889Scopus ID
2-s2.0-84958899793 (requires institutional sign-in at Scopus site) 55 CitationsAbstract
The introduction of chimeric antigen receptor (CAR)-modified T cells has revolutionized immunotherapy and cancer treatment as a whole. However, so far, clinical efficacy has only been demonstrated for CD19-positive B cell lymphomas. For Multiple Myeloma (MM), the second most common haematological malignancy, there are currently no clinical results supporting the usefulness of the adoptive transfer of CAR-modified T cells. This might be related to the fact that an ideal surface target has not yet been identified or the presence of strong local immunosuppression in the tumour microenvironment, which is a hallmark of MM. In this review, we provide a comprehensive overview of promising target molecules for CAR T cell approaches in MM and we outline a number of ways in which the local immunosuppression in MM can be overcome. By providing a strategy for the design of CAR T cell treatments for MM we hope to transform this new therapeutic approach into a valuable tool within the therapeutic armamentarium for MM.
Author List
Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens TAuthor
Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Genetic EngineeringGenetic Therapy
Humans
Immunotherapy, Adoptive
Multiple Myeloma
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
T-Lymphocytes
